- Home
- LPRO vs FHTX Comparison
LPRO vs FHTX Comparison
Compare LPRO & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPRO
- FHTX
- Stock Information
- Founded
- LPRO 2000
- FHTX 2015
- Country
- LPRO United States
- FHTX United States
- Employees
- LPRO N/A
- FHTX N/A
- Industry
- LPRO Finance: Consumer Services
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- LPRO Finance
- FHTX Health Care
- Exchange
- LPRO Nasdaq
- FHTX Nasdaq
- Market Cap
- LPRO 232.4M
- FHTX 278.1M
- IPO Year
- LPRO N/A
- FHTX 2020
- Fundamental
- Price
- LPRO $2.12
- FHTX $5.01
- Analyst Decision
- LPRO Buy
- FHTX Strong Buy
- Analyst Count
- LPRO 6
- FHTX 8
- Target Price
- LPRO $3.44
- FHTX $12.63
- AVG Volume (30 Days)
- LPRO 794.4K
- FHTX 117.9K
- Earning Date
- LPRO 08-06-2025
- FHTX 08-15-2025
- Dividend Yield
- LPRO N/A
- FHTX N/A
- EPS Growth
- LPRO N/A
- FHTX N/A
- EPS
- LPRO N/A
- FHTX N/A
- Revenue
- LPRO $17,672,000.00
- FHTX $23,504,000.00
- Revenue This Year
- LPRO $314.67
- FHTX $33.60
- Revenue Next Year
- LPRO $15.32
- FHTX $5.87
- P/E Ratio
- LPRO N/A
- FHTX N/A
- Revenue Growth
- LPRO N/A
- FHTX N/A
- 52 Week Low
- LPRO $0.70
- FHTX $2.95
- 52 Week High
- LPRO $6.92
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- LPRO 39.43
- FHTX 40.37
- Support Level
- LPRO $2.04
- FHTX $6.00
- Resistance Level
- LPRO $2.70
- FHTX $6.79
- Average True Range (ATR)
- LPRO 0.17
- FHTX 0.42
- MACD
- LPRO -0.06
- FHTX -0.16
- Stochastic Oscillator
- LPRO 12.12
- FHTX 3.37
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.